We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
The investor discussions surrounding Oxford Biomedica Plc (OXB) have centered on the company's recent developments and the overarching sentiment regarding its strategic position within the biopharmaceutical sector. A significant highlight from these conversations is the ongoing speculation around potential bids from larger players, likely aimed at bolstering their manufacturing capabilities. A contributor pointed out the interesting dynamics at the AGM, suggesting that there was a "feeling of potential vulnerability to an opportunistic bid," emphasizing that OXB's small-cap status may render it susceptible to acquisition attempts by mega-cap firms. The discussions reflect a broader concern among investors about OXB's share price performance and its positioning amid competitive pressures within the cell and gene therapy contract development and manufacturing organization (CDMO) space.
Financially, investors noted that OXB has projected sales of approximately £180 million for the upcoming year, which may signal a robust recovery plan after challenging periods. Several quotes echoed investor sentiment on this topic, with one user stating, "a record revenue year" could substantially enhance the company's valuation. Others provided mixed predictions for share price targets, with estimates ranging from £5.50 to as high as £10 over the next year, reflecting differing levels of optimism about OXB's ability to leverage its capabilities under current market conditions. Overall, the sentiment appears cautious yet hopeful, with a significant focus on upcoming strategic decisions and events, such as potential partnerships or acquisitions that could reshape the company’s trajectory.
Show more
Oxford Biomedica Plc (OXB) announced in a recent update that as of November 30, 2024, its issued share capital consists of 105,938,933 ordinary shares, with no shares held in treasury. This figure is important for shareholders as it serves as the denominator for calculating their obligations under the FCA's Disclosure Guidance and Transparency Rules regarding notifications of interest or changes in their interest in the company.
This announcement signals OXB's ongoing compliance with regulatory requirements as a public company while also providing shareholders with key information necessary for their governance and investment decisions. The company continues to focus on expanding its capabilities in the cell and gene therapy sectors, aiming to leverage its infrastructure for growth in the competitive market landscape.
Show more
No great surprise that low, and better than the techmark index I suppose :) |
Well spotted Cousin. |
So Columbia Threadneedle (per the RNS detail) were down as 3.06% in the OXB annual report, so have built another 2% over the last 6 months or so. Their business also now includes the old F&C/I&S/BMO funds but not sure where the OXB position held. |
Ameriprise Financial, Inc. is an American diversified financial services company and bank holding company based in Minneapolis, Minnesota.[1] It provides financial planning products and services, including wealth management, asset management, insurance, annuities, and estate planning.[1]As of April 2022, more than 80% of the company's revenue came from wealth management.[1][2]Ame |
Honestly never heard of them Tricky, but |
So our accumulator is unveiled. |
Not impossible - interesting just how few firms from the health sector are linked to FTSE 250...look at the big investors in this area e.g. Mercantile IT close to zero investment in this sector and as you look at all the other names it follows a very similar pattern. |
takeiteasy, |
Not all of us.... |
All this talk about US politics has scared all the OXB punters off today - they must read into this BB that the die hards have lost interest and are bored :) |
Time to let politics go and concentrate on our favourite subject, dear OXB. Til the morning, yn y bore! Looking forward to fireworks this week!!!! |
I promise to get back to OXB tomorrow and shut up about current events (or at least give it a try). |
I have never looked to political leaders to be examples of moral rectitude or providers of moral guidance.From feted heroes of distant history,to the likes of Lloyd George and JFK,flawed individuals have achieved power.I don't even expect to learn the complete truth.Russian missiles in Cuba in 63 but no mention of US missiles in Turkey,weapons of mass destruction in Iraq ,we are drip fed selective information so we will conclude what powerful lobbies,political and military,want us to believe.I'm not a conspiracy theorist but i do believe that the powers that be,invariably connive to keep the general public pretty much in the dark,exaggerating this and underplaying that,according to their agenda.A benign dictatorship seems increasingly acceptable in my advancing years :) |
sj, |
This is just a bit of oversimplified misinformation that is popular on twitter and actually stands up to very little scrutiny. |
Yes GJ , it's amazing that anyone with 34 felony convictions and a rape conviction, who incited an insurrection, sold "Top-Secret" files to foreign nations, and an inveterate lying thief could EVER be considered a candidate for POTUS. I guess we live and learn...🤔 |
The office of President of the USA should be greater than the President who holds it. Many poor presidents have at least held the office well. Others have demeaned the office they serve. |
Harry,Yes, I did watch the videos of the riots, and they very much confirmed all that I had read and seen before.Some people acted in what appeared to be almost bemused good nature, but others were out for blood. However, five people died, so it was serious, but Trump thought not. That sums him up. I'm a full blooded right of center libertarian, but could never support a man like that, even in the face of a Harris shaped alternative.And yes, you are right about the risks of Greece: like many previously communist led countries, it has history of expropriation! My (half hearted) musings have everything in excess of living expenses simply moved straight away from the SIPP into Overseas Bonds, domiciled in Guernsey, which would remove that risk. (Anyone else here got experience of those vehicles? SIPPs and ISA's have pushed them off the radar, but with labour in power I think that may change).And yes too to your observations regarding European migration: almost (?!) as much a mess as in the UK. At the moment, Greece (Crete) is home to a huge number of (illegal) migrants from Albania, Morocco, and Georgia. Everyone else moves on, hoping to get to Germany, Sweden or the UK, which are seen as the easy touches. |
red, |
Good to have so many supporters of Mr Trump here. He is a hero. He will round up all the immigrants and liquidate every last one of them. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions